

PU3611USw

2

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Original) Enantiomerically enriched 3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid, or a pharmaceutically acceptable salt or solvate thereof.
2. (Original) The enantiomerically enriched compound of Claim 1 wherein the (+) enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 90% of said compound.
3. (Previously presented) The enantiomerically enriched compound of Claim 2, wherein the (+) enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 99% of said compound.
4. (Previously presented) A pharmaceutical composition comprising the enantiomerically enriched compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers and or excipients.
5. (Amended) A method for treating a CCK-A mediated disease or condition comprising administration to a mammal an effective amount of compound as claimed in claim 1, wherein said disease or condition is obesity, gallbladder stasis, or diabetes.


PU3611USw

3

6. (Amended) A method for treating a CCK-A mediated disease or condition comprising administration to a mammal a pharmaceutical composition as claimed in Claim 4, wherein said disease or condition is obesity, gallbladder stasis, or diabetes.
7. (Amended) The method as claimed in claim 5, wherein said disease or condition is obesity, ~~gallbladder stasis, or diabetes.~~
8. (Amended) The method as claimed in claim 5 6, wherein said disease or condition is obesity.
9. (Previously cancelled).
10. (Amended) A process for the preparation of a compound of claim 1 which comprises:
 - (a) resolution of racemic 3-[3-[1-(isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido]benzoic acid by chiral hplc;
 - (b) reaction of the appropriate enantiomer of the amine of formula (II)


PU3611USw

4




(II)


with (i) the isocyanate of formula (III), (ii) the imidazolidine of formula (IV), or optionally substituted (iii) the unsubstituted phenyl carbonate of formula (V) or the substituted phenyl carbonate of formula (V) wherein R₁ is hydrogen or NO₂



(III)



(IV)




(V)

followed by removal of the carboxy protecting group R.

PU3611USw

5


11. (Previously amended) A process according to claim 10 wherein said preparation is via the racemic amine (II) which has been prepared by concomitant reduction and hydrogenolysis of the oxime (VI),




(VI)

wherein R_2 is ~~an optionally substituted benzyl group~~, p-methoxybenzyl, or benzylhydryl.

12. (Previously amended) A process according to claim 11 wherein the oxime (VI) is prepared from the ortho phenylene diamine (VII) and an activated derivative of the diacid (VIII) wherein said activated derivative is the corresponding diacyl halide.



(VII)



(VIII)

PU3611USw

6

wherein R_2 is an ~~optionally substituted benzyl group~~, p-methoxybenzyl,
or benzylhydryl.

13. (Previously cancelled).